Progenra
  • About
    • Investor Relations
    • Leadership
  • Therapeutic Focus
    • The Ubiquitin Proteasome System (UPS)
    • UbiPro™ Platform
    • PROTAC Platform
    • Therapeutic Areas
  • Partnering
    • The Progenra Advantage
    • Partnering Opportunities
    • Collaborations
  • Careers
    • R&D, Biology
    • R&D, Medicinal Chemistry
  • News
    • News
    • Meetings
    • Publications
  • Blog
Select Page

Progenra invited to host an Immune Oncology Session at BIO International Convention 2017

by admin | Jun 18, 2017 | News

June 18-22, 2017. San Diego, CA.  Progenra President Dr. Tauseef Butt is the organizer and a participant of a panel discussion entitled “Immune Oncology Drugs: Ready for First Line Therapy?” This panel, which is comprised of leaders of immune oncology from the...

Recent Posts

  • Characterization of Selective Covalent inhibitors of USP7- AACR Poster
  • Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
  • Immune Regulation by Protein Ubiquitination: Roles of the E3 Ligases VHL and Itch
  • Protein Misfolding-Neurodegeneration
  • Ubiquitination and Cancer

Archives

  • May 2019
  • December 2018
  • April 2018
  • March 2018
  • September 2017
  • June 2017
  • May 2017
  • December 2016
  • December 2015

Contact

  610.644.6974
  610.644.8616
   277 Great Valley Parkway
      Malvern PA, 19355

For More Information

  info@progenra.com
  bd@progenra.com
      (Business Development inquries)
  • Facebook
  • Twitter
  • LinkedIn
© 2019 Progenra Inc. All Rights Reserved.
Website Designed by eNet Web Services